- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04280562
Remote Participation (Within USA) Trial of Sana Pain Reliever
Extended Home-use Trial of a Novel Device to Reduce Chronic Neuropathic Pain
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Laura Tabacof, MD
- Phone Number: 2122418545
- Email: laura.tabacof@mountsinai.org
Study Contact Backup
- Name: Patrycja Graczyk
- Phone Number: (929) 618-0583
- Email: Patrycja.Graczyk@mountsinai.org
Study Locations
-
-
New York
-
New York, New York, United States, 10011
- Icahn School of Medicine at Mount Sinai
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Confirmed clinical diagnosis of neuropathic pain
- Age of 18 years or older at time of consent
- Fluent in English
- Consistent medications for the last 4 weeks prior to the first baseline visit (week 0)
Exclusion Criteria:
- Diagnosis of photosensitive epilepsy
- Active ear or eye infection
- Vision impairments that affect perception of light in one or both eyes
- Deafness in one or both ears
- Severe depression (Score higher than 30 points on the Beck's Depression Inventory)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: "Real" SPR
Participants will receive the device which will run the "real" Sana Pain Reliever (SPR) protocol and a tablet with a mobile application to record pain levels and other questionnaires
|
Participants will receive the SPR device and a tablet with instructions of how to use the device and how to answer the questionnaires on the tablet mobile application.
Each session with the device will last 16 minutes and run under the device's normal settings.
The session consists of periods of light and sounds (beeps).
Participants will be instructed to use the device each day at the end of the day prior to going to sleep and whenever they experience heightened pain during the day.
|
Sham Comparator: Sham SPR
Participants will receive the device which will run a sham SPR protocol and a tablet with a mobile application to record pain levels and other questionnaires
|
Participants will receive the SPR device and a tablet with instructions of how to use the device and how to answer the questionnaires on the tablet mobile application.
Each session with the device will last 16 minutes and run under the device's sham settings.
The session consists of periods of light and sounds (beeps).
Participants will be instructed to use the device each day at the end of the day prior to going to sleep and whenever they experience heightened pain during the day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Neuropathic Pain Symptom Inventory (NPSI)
Time Frame: Baseline 1(Week0); Baseline 2 (Week 2); Post-assessment (Week 10); Follow up (Week 14)
|
This scale was developed to assess both the quantitative and qualitative qualities of neuropathic pain (NP).
It includes 12 items, assessing spontaneous pain, brief attacks of pain, provoked pain and abnormal sensations in the painful area.
This is a sensitive tool for measuring changes in neuropathic pain after a therapeutic intervention.
Full scale from 0-10 with higher score indicating more symptom.
Change in score at Week 2, Week 10 and Week 14 as compared to Baseline.
|
Baseline 1(Week0); Baseline 2 (Week 2); Post-assessment (Week 10); Follow up (Week 14)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Patient health Questionnaire Type 9 for Depression (PHQ-9)
Time Frame: Baseline 1(Week0); Baseline 2 (Week 2); Post-assessment (Week 10); Follow up (Week 14)
|
The Questionnaire Type 9 for Depression (PHQ-9) is a self-administered version of the PRIME-MD diagnostic instrument for common mental disorders.
The PHQ-9 is the depression module, which scores each of the nine DSM-IV criteria as "0" (not at all) to "3" (nearly every day).
It has been validated for use in primary care and is used to monitor the severity of depression and response to treatment.
Full scale from 0-27, with higher score indicating more severe symptoms.
Change in score at Week 2, Week 10 and Week 14 as compared to Baseline.
|
Baseline 1(Week0); Baseline 2 (Week 2); Post-assessment (Week 10); Follow up (Week 14)
|
Change in Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Baseline 1(Week0); Baseline 2 (Week 2); Post-assessment (Week 10); Follow up (Week 14)
|
The Pittsburgh Sleep Quality Index (PSQI) is an effective instrument used to measure the quality and patterns of sleep in adults.
It differentiates "poor" from "good" sleep quality by measuring seven areas (components): subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction over the last month.
Full score from 0-21, with higher score indicating worse sleep quality.
Change in score at Week 2, Week 10 and Week 14 as compared to Baseline.
|
Baseline 1(Week0); Baseline 2 (Week 2); Post-assessment (Week 10); Follow up (Week 14)
|
Change in Beck Depression Inventory (BDI)
Time Frame: Baseline 1(Week0); Baseline 2 (Week 2); Post-assessment (Week 10); Follow up (Week 14)
|
The Beck Depression Inventory (BDI) is used to evaluate depression symptoms, which are estimated to be highly prevalent in chronic pain populations.
This questionnaire is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression.
Depression may be a major contributor to a lack of reduction of pain.
Scoring is from 0 (minimal) to 3 (severe), with total score from 0-63.
Higher total scores indicate more severe depressive symptoms.
Change in score at Week 2, Week 10 and Week 14 as compared to Baseline.
|
Baseline 1(Week0); Baseline 2 (Week 2); Post-assessment (Week 10); Follow up (Week 14)
|
Change in General Anxiety Disorder 7-item questionnaire (GAD-7)
Time Frame: Baseline 1(Week0); Baseline 2 (Week 2); Post-assessment (Week 10); Follow up (Week 14)
|
The General Anxiety Disorder 7-item questionnaire (GAD-7) is a 7-item questionnaire that asks user to rank how often they have been bothered by seven problems over the past two weeks from "0" (not at all) to "3" (nearly every day).
The items that users are asked to rank levels of nervousness, anxiousness, relaxing, restlessness, irritability and fearfulness.
Full scale from 0-21, with higher score indicating more symptoms.
Change in score at Week 2, Week 10 and Week 14 as compared to Baseline.
|
Baseline 1(Week0); Baseline 2 (Week 2); Post-assessment (Week 10); Follow up (Week 14)
|
Change in World Health Organization Quality of Life Pain (WHOQOL-pain)
Time Frame: Baseline 1(Week0); Baseline 2 (Week 2); Post-assessment (Week 10); Follow up (Week 14)
|
World Health Organization Quality of Life BREF(WHOQOL-BREF) & World Health Organization Quality of Life Pain (WHOQOL-pain): The WOQOL-BREF is a used to produce a quality of life profile for an individual that is derived from four domains.
There are 26 questions which ask users to respond to quality of life (Q.o.L) questions on a scale of 1-5 (1-Not at All, Very Poor, or Very Dissatisfied; 5- Completely, Very Good, or Very Satisfied).
The WHOQOL-pain scale is to be used in addition to the WHOQOL-BREF which a specific focus on the impact of pain on Q.o.L.
The WHOQOL-pain has 22 items on the pain and discomfort module (PDM) and the importance of items within a user's daily life.
Full scale from 0-100 with higher score indicating higher quality of life.
Change in score at Week 2, Week 10 and Week 14 as compared to Baseline.
|
Baseline 1(Week0); Baseline 2 (Week 2); Post-assessment (Week 10); Follow up (Week 14)
|
Change in World Health Organization Quality of Life Bref (WHOQOL-BREF)
Time Frame: Baseline 1(Week0); Baseline 2 (Week 2); Post-assessment (Week 10); Follow up (Week 14)
|
World Health Organization Quality of Life BREF(WHOQOL-BREF) & World Health Organization Quality of Life Pain (WHOQOL-pain): The WHOQOL-BREF is a used to produce a quality of life profile for an individual that is derived from four domains.
There are 26 questions which ask users to respond to quality of life (Q.o.L) questions on a scale of 1-5 (1-Not at All, Very Poor, or Very Dissatisfied; 5- Completely, Very Good, or Very Satisfied).
The WHOQOL-pain scale is to be used in addition to the WHOQOL-BREF which a specific focus on the impact of pain on Q.o.L.
The WHOQOL-pain has 22 items on the pain and discomfort module (PDM) and the importance of items within a user's daily life.
Full scale from 0-100 with higher score indicating higher quality of life.
Change in score at Week 2, Week 10 and Week 14 as compared to Baseline.
|
Baseline 1(Week0); Baseline 2 (Week 2); Post-assessment (Week 10); Follow up (Week 14)
|
Change in Patient's Global Impression of Change (PGIC)
Time Frame: Post-assessment (Week 10); Follow up (Week 14)
|
The Patient's Global Impression of Change (PGIC) will be used to assess self-reported relieving effect.
It will evaluate pain from no change (score 0-1), minimally improved (score 2-3), much improved (score 4-5), and very much improved (score 6-7).
The patients will answer the following question: "Since beginning treatment at this program, how would you describe the change (if any) in activity limitations, symptoms, emotions, and overall quality of life related to your condition?".
Full score from 0-7, with higher score indicating more improvement.
Change in score at Week 14 as compared to Week 10.
|
Post-assessment (Week 10); Follow up (Week 14)
|
Visual analogue scale (VAS)-Pain
Time Frame: VAS-Pain: before and after each time they use the device up to 14 weeks
|
Visual Analog Scale (VAS) to measure pain: a measure of "no pain" to "Worst pain imaginable" along a line. Participants will be asked to mark the level of their pain along the line. Visual Analog Scale (VAS) to measure sleep: a measure of "did not sleep at all" to "best possible night's sleep" along a line. Participants will be asked to mark the level of their sleep along the line. The Sana Health application will prompt users to answer this scale before they use the device for the first time each day. Full scale from 0-10 with higher score indicating more pain. |
VAS-Pain: before and after each time they use the device up to 14 weeks
|
Visual analogue scale (VAS)-Sleep
Time Frame: VAS-Sleep: once/day up to 14 Weeks
|
Visual Analog Scale (VAS) to measure pain: a measure of "no pain" to "Worst pain imaginable" along a line. Participants will be asked to mark the level of their pain along the line. Visual Analog Scale (VAS) to measure sleep: a measure of "did not sleep at all" to "best possible night's sleep" along a line. Participants will be asked to mark the level of their sleep along the line. The Sana Health application will prompt users to answer this scale before they use the device for the first time each day. Full scale from 0-10 with higher score indicating more pain. |
VAS-Sleep: once/day up to 14 Weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: David Putrino, PT, PhD, Icahn School of Medicine at Mount Sinai
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GCO 18-2282
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
Clinical Trials on Sana Pain Reliever
-
Sana HealthUniversity of PennsylvaniaNot yet recruitingQuality of Life | Fibromyalgia | Pain, Chronic
-
Stanford UniversityPatient-Centered Outcomes Research Institute; San Mateo Medical CenterRecruiting
-
ThuasneUniversity Hospital of Saint-Etienne; Laboratoire Interuniversitaire de Biologie...Completed
-
Sana HealthRalph H. Johnson VA Medical CenterCompletedPost Traumatic Stress DisorderUnited States
-
ThuasneCompletedOsteoarthritis, KneeFrance
-
Palo Alto Medical FoundationUniversity of Pittsburgh; University of Illinois at Chicago; RTI International; Agency for Healthcare Research and Quality (AHRQ) and other collaboratorsCompletedInsulin Resistance | Prediabetic State | Metabolic Syndrome X
-
Sana HealthDuke UniversityCompleted
-
University of California, DavisCompleted
-
University of Toledo Health Science CampusTerminatedVenous Wound UlcersUnited States
-
Wake Forest University Health SciencesCompleted